Novartis posted revenue of $12.13 billion, a drop of 1.1% Y-o-Y, and missing the forecast by $110 million. EPS stood at $1.23, beating the forecast by $0.04. Performance of various units: Oncology: (-6.2%); Ophthalmology: (-0.2%); Est. Medicines: (-17.5%); Neuroscience: (+3.9%); Immunology & Dermatology: (+37.7%); Respiratory: (+18.9%); Cardio-Metabolic: (+22.2%).